Christoph Esslinger
Fondatore presso Memo Therapeutics AG
Posizioni attive di Christoph Esslinger
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Fondatore | 29/11/2012 | - |
| Direttore Tecnico/Scientifico/R&S | 29/11/2012 | - | |
| Direttore/Membro del Consiglio | 29/11/2012 | - |
Storia della carriera di Christoph Esslinger
Precedenti posizioni note di Christoph Esslinger
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| Neurimmune Therapeutics | Corporate Officer/Principal | - | - |
CT Atlantic Ltd.
 CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Direttore Tecnico/Scientifico/R&S | 17/09/2009 | - |
| Fondatore | 17/09/2009 | - |
Formazione di Christoph Esslinger
| University of Lausanne | Doctorate Degree |
| Universität Stuttgart | Graduate Degree |
Statistiche
Distribuzione geografica
| Svizzera | 5 |
| Germania | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 1 |
Settori
| Consumer Services | 3 |
| Commercial Services | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 3 |
|---|---|
CT Atlantic Ltd.
CT Atlantic Ltd. Miscellaneous Commercial ServicesCommercial Services CT Atlantic AG focuses on the identification and development of human-derived monoclonal antibodies as novel therapeutics for the treatment of cancer. The company was founded by Alexander Knuth, Christoph Esslinger and Edward Stuart in 2008 and is headquartered in Schlieren, Switzerland. | Commercial Services |
| Neurimmune Therapeutics | |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- Christoph Esslinger
- Esperienza
